NetworkNewsBreaks – Zenosense, Inc. (ZENO) MIDS

NetworkNewsBreaks – Zenosense, Inc. (ZENO) MIDS Cardiac Device Could Spare Patients from Unnecessary Evaluation Expenses

Healthcare technology company Zenosense (OTC: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (“MML”) and its innovative handheld MIDS technology, is engaged in the ongoing development of its innovative MIDS Cardiac device. A recent article about the company reads: “MIDS Cardiac aims is to deliver true laboratory accuracy, performing high-sensitivity troponin tests in the emergency room or out in the field to better identify if a patient with chest pain or shortness of breath is experiencing a myocardial infarction. Troponin is a heart protein generally searched for by emergency room physicians as a quick indicator if damaged cardiac cells have entered the blood stream, and new age high-sensitivity troponin tests are delivering critical information to doctors more rapidly than before. … The majority of patients presenting themselves with chest pain or shortness of breath are ultimately found to not be experiencing acute heart attacks, but the critical concern associated with their symptoms can lead to unnecessary hospital admissions and tests that increase the medical expenses borne largely by patients and their insurance providers.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer